Mesoblast Reports Successful Launch of Ryoncil® and Expands Pipeline Efforts

An update from Mesoblast Limited ( (AU:MSB) ) is now available.

Mesoblast Limited announced the successful commercial launch of Ryoncil®, the first FDA-approved mesenchymal stromal cell product in the U.S., generating $13.2 million in revenue in its first quarter. The company has onboarded over 25 transplant centers and aims to complete onboarding across 45 centers, covering 80% of U.S. pediatric transplants. Ryoncil® has received orphan-drug exclusivity for seven years, preventing competition in its indication. Mesoblast is also advancing its pipeline with ongoing trials for heart failure and chronic low back pain, and is working towards expanding Ryoncil®’s label to include adults with SR-aGvHD.

The most recent analyst rating on (AU:MSB) stock is a Buy with a A$1.10 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.

More about Mesoblast Limited

Mesoblast Limited is a global leader in developing allogeneic cellular medicines for severe and life-threatening inflammatory conditions. The company specializes in mesenchymal stromal cell (MSC) therapies, which release anti-inflammatory factors to modulate immune responses. Mesoblast’s Ryoncil® is the first FDA-approved MSC therapy for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients. The company is also developing therapies for other inflammatory diseases and has established commercial partnerships in Japan, Europe, and China.

Average Trading Volume: 5,231,849

Technical Sentiment Signal: Hold

Current Market Cap: A$2.17B

For a thorough assessment of MSB stock, go to TipRanks’ Stock Analysis page.